Edwards Lifesciences, Wolfe

Edwards Lifesciences downgraded at Wolfe on TAVR worries
Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device maker, citing concerns over its prospects in the market for Transcatheter Aortic Valve Replacement (TAVR).
Do You Believe in the Growth Prospects of Edwards Lifesciences Corporation (EW)?
Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, Wedgewood Composite’s net return was 5.
Edwards Lifesciences downgraded to Underperform at Wolfe Research
Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core
Should Edwards Lifesciences Stock Stay in Your Portfolio Now?
EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.
Edwards Lifesciences Corp (EW) Stock Sees Market Value Hit $41.93 billion: What Are the Implications?
Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $71.09 which represents a decrease of $-2.33 or -3.17% from the prior close of $73.42. The stock opened at $70.54 and touched a low of $69.
Bernstein Reaffirms Their Hold Rating on Edwards Lifesciences (EW)
In a report released yesterday, Lee Hambright from Bernstein maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The
Wolfe Research Downgrades Edwards Lifesciences (EW)
Fintel reports that on January 16, 2025, Wolfe Research downgraded their outlook for Edwards Lifesciences (NYSE:EW) from Peer Perform to Underperform. Analyst Price Forecast Suggests 14.75% Upside As of December 23,
Wolfe Research cuts Edwards Lifesciences stock rating to Underperform
Wolfe Research adjusted its perspective on Edwards Lifesciences (NYSE:EW) shares, downgrading its rating from Peerperform to Underperform. The firm also set a price target of $60.00 for the medical technology company's stock,
Edwards Lifesciences CVP Daniel Lippis sells $34,382 in stock
Daniel J. Lippis, the Corporate Vice President for JAPAC at Edwards Lifesciences Corp (NYSE:EW), has disclosed recent stock ...
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day
This was the stock's fourth consecutive day of losses.
High Court Axes Edwards' Bid to Limit Drug-Patent Safe Harbor
The US Supreme Court rejected a case asking the justices to interpret a patent-infringement safe-harbor provision in a ...
Forbes1d
Edwards Lifesciences
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...
Capital Investment Advisors LLC Sells 143 Shares of Edwards Lifesciences Co. (NYSE:EW)
Capital Investment Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the ...
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors despite daily gains
Edwards Lifesciences Corp. closed $22.48 below its 52-week high ($96.12), which the company reached on March 28th.
IPWatchdog3d
Supreme Court Denies Petitions on Hatch-Waxman Safe Harbor, ITC Economic Prong Analysis and Stay of Federal Trade Secret Claims
On Monday, January 13, the U.S. Supreme Court issued an order list denying petitions for writ of certiorari in three cases ...
Equities Analysts Set Expectations for EW FY2024 Earnings
Zacks Research raised their FY2024 earnings per share (EPS) estimates for Edwards Lifesciences in a research note issued on ...